| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Purchase of treasury stock | 29,462 | 29,462 |
| Net cash provided by (used in) financing activities | 2,317,886 | 1,280,538 |
| Net change in cash | 709,694 | 399,678 |
| Cash and cash equivalents at beginning of period | 916,916 | - |
| Cash and cash equivalents at end of period | 1,626,610 | - |
Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc. (ESLA)